LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,773,407
تعداد دریافت فایل اصل مقاله8,801,144
Omidvari, Shapour, Hosseini, Sare, Ashouri, Yaghoub, Tahmasebi, Sedigheh, Talei, Abdolrasoul, Nasrolahi, Hamid, Ahmadloo, Niloofar, Ansari, Mansour, Mosalaei, Ahmad, Mohammadianpanah, Mohammad. (1390). Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial. سامانه مدیریت نشریات علمی, 2(2), 51-58.
Shapour Omidvari; Sare Hosseini; Yaghoub Ashouri; Sedigheh Tahmasebi; Abdolrasoul Talei; Hamid Nasrolahi; Niloofar Ahmadloo; Mansour Ansari; Ahmad Mosalaei; Mohammad Mohammadianpanah. "Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial". سامانه مدیریت نشریات علمی, 2, 2, 1390, 51-58.
Omidvari, Shapour, Hosseini, Sare, Ashouri, Yaghoub, Tahmasebi, Sedigheh, Talei, Abdolrasoul, Nasrolahi, Hamid, Ahmadloo, Niloofar, Ansari, Mansour, Mosalaei, Ahmad, Mohammadianpanah, Mohammad. (1390). 'Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial', سامانه مدیریت نشریات علمی, 2(2), pp. 51-58.
Omidvari, Shapour, Hosseini, Sare, Ashouri, Yaghoub, Tahmasebi, Sedigheh, Talei, Abdolrasoul, Nasrolahi, Hamid, Ahmadloo, Niloofar, Ansari, Mansour, Mosalaei, Ahmad, Mohammadianpanah, Mohammad. Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial. سامانه مدیریت نشریات علمی, 1390; 2(2): 51-58.

Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial

Middle East Journal of Cancer
مقاله 2، دوره 2، شماره 2، تیر 2011، صفحه 51-58    اصل مقاله (135.6 K)
نوع مقاله: Original Article(s)
نویسندگان
Shapour Omidvari1؛ Sare Hosseini1؛ Yaghoub Ashouri1؛ Sedigheh Tahmasebi2؛ Abdolrasoul Talei2؛ Hamid Nasrolahi1؛ Niloofar Ahmadloo1؛ Mansour Ansari1؛ Ahmad Mosalaei1؛ Mohammad Mohammadianpanah* 1
1Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: The present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (TAC) vs. 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) as neoadjuvant chemotherapy in women with locally advanced breast cancer. Methods: One hundred women with pathologically confirmed newly diagnosed locally advanced (T3-T4 or N2-N3) breast cancer were randomly assigned to receive a median of four cycles of either 5-fluorouracil (600 mg/m2), doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every three weeks or docetaxel (75 mg/m2), doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every three weeks followed by modified radical mastectomy. Complete clinical and pathologic response rates and toxicity were the primary and secondary outcome measures of the study.Results: Median age for all patients was 43.4 years (range 25-63 years). Patients in the TAC arm achieved a higher clinical (16%) response rate than those in the FAC arm (4%, P=0.046). The pathologic response rate was also higher in the TAC arm compared to the FAC arm [TAC (20%) vs. FAC (6%), P=0.037]. Estrogen receptor- negative status correlated with a higher clinical [TAC (19%) vs. FAC (4%), P=0.032] and pathologic [TAC (23%) vs. FAC (4%), P=0.011)] response rate in both arms. All patients generally tolerated treatment well, and treatment-related toxicities were manageable.Conclusion: Combined treatment with TAC led to higher rates of complete clinical and pathologic response with acceptable toxicity compared to FAC in patients with locally advanced breast cancer. However, further follow-up is needed to translate this response into improvements in survival.
آمار
تعداد مشاهده مقاله: 3,791
تعداد دریافت فایل اصل مقاله: 1,303


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب